Sanofi (SNY)

43.21
NYSE : Health Technology
Prev Close 43.21
Day Low/High 0.00 / 0.00
52 Wk Low/High 37.43 / 45.86
Avg Volume 1.27M
Exchange NYSE
Shares Outstanding 2.58B
Market Cap 109.90B
EPS 1.70
P/E Ratio 23.43
Div & Yield 1.20 (2.84%)
After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

After Stunning Loss to Amgen in Patent Case, Regeneron Plans to Join Sanofi in Appeal

A federal judge has banned the sale of Regeneron's cholesterol-lowering drug Praluent, handing a surprise and overwhelming victory to Amgen and its competing drug Repatha in a long-running patent lawsuit.

European Stocks Open Lower as Investors Prep for U.S. Jobs Report

European Stocks Open Lower as Investors Prep for U.S. Jobs Report

European shares open with a defensive tone ahead of U.S. December nonfarm payrolls; Sanofi slumps on the Praluent injunction.

(Graphic: Business Wire)

(Graphic: Business Wire)

Sanofi and Boehringer Ingelheim confirmed today that the strategic transaction signed in June 2016, which consists of an exchange of Sanofi's animal health business (Merial) and Boehringer Ingelheim's consumer...

Actelion's Fate May Rest on Structure, Not Price, as Clozel Holds Firm

Actelion's Fate May Rest on Structure, Not Price, as Clozel Holds Firm

Actelion's CEO has held control at the company he founded, but its largest shareholder has ties with Johnson & Johnson.

5 Things You Must Know Before the Market Opens Thursday

5 Things You Must Know Before the Market Opens Thursday

U.S. stock futures post slight losses as investors await data on U.S. growth and durable goods; Carl Icahn is named special adviser to President-elect Donald Trump on overhauling federal regulations.

Actelion Hits Record High After Confirming Exclusive Talks With Johnson & Johnson

Actelion Hits Record High After Confirming Exclusive Talks With Johnson & Johnson

Shares in the biotech firm hit a record high Thursday after confirming 'exclusive' talks with Johnson & Johnson.

European Stocks Drift Lower in Holiday-Thinned Trading

European Stocks Drift Lower in Holiday-Thinned Trading

European stocks are likely to post modest losses Thursday as a slower holiday trading pace takes over regional markets.

Dow's Ascent to 20,000 Milestone Hits Snag

Dow's Ascent to 20,000 Milestone Hits Snag

The Dow Jones Industrial Average's steady path to its 20,000 milestone hit the pause button on Wednesday after a meandering day of slight losses.

Stocks Sport Slight Losses as Dow's Journey to 20,000 Pauses

Stocks Sport Slight Losses as Dow's Journey to 20,000 Pauses

Stocks hold slightly lower on Wednesday as the Dow Jones Industrial Average hovers around 40 points below its 20,000 milestone.

Actelion Restarts Possible Merger Talks With Johnson & Johnson

Actelion Restarts Possible Merger Talks With Johnson & Johnson

The Swiss biotech says it's in exclusive talks with J&J about a possible 'strategic transaction.'

Actelion Shares Rise Amid Speculation on Possible Improved Sanofi Bid

Actelion Shares Rise Amid Speculation on Possible Improved Sanofi Bid

Shares in the Swiss biotech surge amid reports that Sanofi could use a 'CVR' technique to enhance the potential bid price.

Analysts Mixed on Health Care Stocks in the New Year

Analysts Mixed on Health Care Stocks in the New Year

While there is deep uncertainty about how politics will affect the health care sector in the new year, analysts seem excited about some opportunities in pharmaceuticals.

Innate Pharma Pops as It Names AstraZeneca's Oncology Head as Chairman

Innate Pharma Pops as It Names AstraZeneca's Oncology Head as Chairman

Meanwhile, Astrazeneca's shares fall as its head of oncology leaves for the smaller biotech company.

Disney Stock Upgraded on Force of 'Rogue One's' Huge Opening Weekend

Disney Stock Upgraded on Force of 'Rogue One's' Huge Opening Weekend

The success of its first Star Wars spin-off and other 'blockbuster-level' film releases make Disney a stock to own, according to Bank of America.

The Best Biopharma CEOs of 2016 Are...

The Best Biopharma CEOs of 2016 Are...

The negative investor sentiment for health care stocks in 2016 presented a particularly challenging environment to accomplish anything well. Each of these CEOs met the challenge and succeeded.

Dow on Track for Sixth Straight Week of Gains Even as Markets Fall

Dow on Track for Sixth Straight Week of Gains Even as Markets Fall

The Dow Jones Industrial Average held slight weekly gains on Friday afternoon even in a down day for Wall Street.

Dow Eyes 20,000 as Stocks Drift Higher

Dow Eyes 20,000 as Stocks Drift Higher

Stocks rise on Friday, putting the Dow Jones Industrial Average one step closer to the psychologically important 20,000 level.

5 Things You Must Know Before the Market Opens Friday

5 Things You Must Know Before the Market Opens Friday

U.S. stock futures are mixed while the dollar surges as global markets adjust to higher U.S. interest rates; Facebook plans to fact-check its news; Adobe's earnings top forecasts.

European Stocks Drift Lower; Dollar Dominates Global Financial Markets

European Stocks Drift Lower; Dollar Dominates Global Financial Markets

European stocks are set to book another solid weekly advance amid global market adjustments to the new Fed outlook.

Actelion Stock Hits Record High on Speculation of Sanofi Takeover Approach

Actelion Stock Hits Record High on Speculation of Sanofi Takeover Approach

Actelion stocks surged higher in Zurich amid speculation that France's Sanofi may make a formal approach for the Swiss biotech.

Johnson & Johnson Looks for New Deal That's Just Right

Johnson & Johnson Looks for New Deal That's Just Right

Actelion was too pricey. Now J&J is looking for another acquisition.

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

J&J Is Being Disciplined by Abandoning Merger Talks With Actelion, Jim Cramer Says

Jim Cramer comments on Johnson & Johnson's move to abandon merger talks with Actelion.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are mixed ahead of a decision on interest rates and fresh economic forecasts from the Fed; tech giants meet with Donald Trump; IBM's Rometty promises jobs.

Actelion Shares Plunge After J&J Drops Potential $27 Billion Takeover

Actelion Shares Plunge After J&J Drops Potential $27 Billion Takeover

Actelion confirms the end of talks with J&J over a $27 billion takeover, and market focus shifts to France's Sanofi.

European Stocks Fall as Investors Take Cautious Stance Ahead of Fed Meeting

European Stocks Fall as Investors Take Cautious Stance Ahead of Fed Meeting

European stocks are set to open lower Wednesday ahead of the Fed's final policy meeting of 2016.

5 Things You Must Know Before the Market Opens Tuesday

5 Things You Must Know Before the Market Opens Tuesday

U.S. stock futures trade flat following another record close for the Dow; Amazon reportedly envisions opening 2,000 brick-and-mortar grocery stores; Apple Watch sales set a record, Apple CEO says.

European Stocks Slip Lower, Italy Gains in Mixed Start to Trading

European Stocks Slip Lower, Italy Gains in Mixed Start to Trading

European markets are set for a positive open Tuesday after Asia traders booked their best single-day gains in two weeks.

Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid

Actelion Surges on Report of Sanofi Challenge to J&J Takeover Bid

Actelion shares are on the rise again on reports of a potential counter-bid from France's Sanofi.

Sanofi Genzyme Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma

Sanofi Genzyme Announces Start Of Phase III Study Of Isatuximab For Relapsed And Refractory Multiple Myeloma

Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the initiation of the ICARIA-MM Phase III trial of isatuximab, an investigational anti-CD38 monoclonal antibody being studied for the...

Actelion Shares Fall Sharply on Report It Is Resisting $17 Billion J&J Takeover

Actelion Shares Fall Sharply on Report It Is Resisting $17 Billion J&J Takeover

Actelion shares traded sharply lower Tuesday following reports it's looking at strategies that would keep it independent from a $17 billion approach from Johnson & Johnson.

TheStreet Quant Rating: B (Buy)